SAKK 18/25 (ORIGIN2): Gemcitabine plus Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors
Sponsor: Swiss Cancer Institute
Phase: 2
Disease: Non-small cell lung cancer, Squamous non-small cell lung carcinoma, Non-squamous non-small cell lung carcinoma
EU trial number: 2026-526043-36-00
Population: Adults with stage IIIB–IV recurrent or progressive squamous or nonsquamous NSCLC after prior immunotherapy, chemotherapy or chemoimmunotherapy, ECOG 0–2 and measurable RECIST 1.1 disease, without actionable EGFR/ALK genomic alterations.
Register Investigator Interest
Interested in offering this trial to suitable patients?